Re-use of the original infusional induction chemotherapy as salvage therapy in myeloma patients relapsing after one autograft

Hematology

Volumn 10, Issue 5, 2005, Pages 361-364

  Sirohi, Bhawna ^a   Powles, Ray ^a,b   Rudin, Claudius ^a   Singhal, Seema ^a,c   Kulkarni, Samar ^a   Saso, Radovan ^a   Horton, Clive ^a   Mehta, Jayesh ^a   Treleaven, Jennifer ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b Parkside Cancer Centre   (United Kingdom)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

C VAMP; Myeloma; Relapse; Salvage therapy

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; MELPHALAN; METHYLPREDNISOLONE; VINCRISTINE;

ADULT; AGED; ARTICLE; AUTOGRAFT; CANCER SURVIVAL; CONTROLLED STUDY; DRUG MEGADOSE; DRUG RESPONSE; FEMALE; HUMAN; INFUSION; MAJOR CLINICAL STUDY; MALE; MYELOMA; PRIORITY JOURNAL; RECURRENT DISEASE; SALVAGE THERAPY; SINGLE DRUG DOSE; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COHORT STUDIES; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; HUMANS; MALE; MELPHALAN; METHYLPREDNISOLONE; MIDDLE AGED; MULTIPLE MYELOMA; RECURRENCE; RETROSPECTIVE STUDIES; SALVAGE THERAPY; TRANSPLANTATION, AUTOLOGOUS; VINCRISTINE;

EID: 29144484348     PISSN: 10245332     EISSN: 16078454     Source Type: Journal    
DOI: 10.1080/10245330500234369     Document Type: Article

References (19)

1. Mehta J, Tricot G, Jagannath S, Ayers D, Singhal S, Siegel D, Desikan K, Munshi N, Fassas A, Mattox S, Vesole D, Crowley J, Barlogie B. Salvage autologous or allogeneic transplantation for multiple myeloma refractory to or relapsing after a first-line autograft? Bone Marrow Transplant 1998;21:887-892.
2. Mehta J, Tricot G, Jagannath S, Desikan KR, Siegel D, Singhal S, Munshi N, Vesole D, Mattox S, Bracy D, Barlogie B. High-dose chemotherapy with carboplatin, cyclophosphamide and etoposide and autologous transplantation for multiple myeloma relapsing after a previous transplant. Bone Marrow Transplant 1997;20:113-116.
3. Richardson PG, Schlossman RL, Weller E, Hideshima T, Mitsiades C, Davies F, LeBlanc R, Catley LP, Doss D, Kelly K, McKenney M, Mechlowicz J, Freeman A, Deocampo R, Rich R, Ryoo JJ, Chauhan D, Balinski K, Zeldis J, Anderson KC. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 2002;100:3063-3067.
4. Richardson PG, Barlogie B, Berenson J, et al. A Phase II multicenter study of the proteasome inhibitor Bortezomib (Velcade, formerly PS-341) in multiple myeloma (MM) patients (pts) with relapsed/refractory disease. Blood 2002;100:104a.
5. Moehler TM, Neben K, Benner A, Egerer G, Krasniqi F, Ho AD, Goldschmidt H. Salvage therapy for multiple myeloma with thalidomide and CED chemotherapy. Blood 2001;98:3846-3848.
6. Barlogie B, Jagannath S, Desikan KR, Mattox S, Vesole D, Siegel D, Tricot G, Munshi N, Fassas A, Singhal S, Mehta J, Anaissie E, Dhodapkar D, Naucke S, Cromer J, Sawyer J, Epstein J, Spoon D, Ayers D, Cheson B, Crowley J. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood 1999;93:55-65.
7. Powles R, Raje N, Milan S, Millar B, Shepherd V, Mehta J, Singhal S, Kulkarni S, Viner C, Gore M, Cunningham D, Treleaven J. Outcome assessment of a population based group of 195 unselected myeloma patients under 70 years of age offered intensive treatment. Bone Marrow Transplant 1997;20:435-443.
8. Dive C, Hickman JA. Drug traget interactions: Only the first step in the commitment of a cell to a programmed cell death. Br J Cancer 1991;64:192-196.
9. Harris AL, Cantwell BM, Carmichael J, Wilson R, Farndon J, Dawes P, Ghani S, Evans RG. Comparison of short-term and continuous chemotherapy (mitozantrone) for advanced breast cancer. Lancet 1990;335:186-190.
10. Muss HB, Case LD, Richards F 2nd White DR, Cooper MR, Cruz JM, Powell BL, Spurr CL, Capizzi RL. Interrupted versus continuous chemotherapy in patients with metastatic breast cancer. N Engl J Med 1991;325:1342-1348.
11. Fisher RI, DeVita VT, Hubbard SP, Simon R, Young RC. Prolonged disease-free survival in Hodgkin's disease with MOPP reinduction after first relapse. Ann Intern Med 1979;90:761-763.
12. Maughan TS, James RD, Kerr DJ, Ledermann JA, Seymour MT, Topham C, McArdle C, Cain D, Stephens RJ; Medical Research Council Colorectal Cancer Group. Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: A multicentre randomised trial. Lancet 2003;361:457.
13. Raje N, Powles R, Kulkarni S, Milan S, Middleton G, Singhal S, Mehta J, Millar B, Viner C, Raymond J, Treleaven J, Cunningham D, Gore M. A comparison of vincristine and doxorubicin infusional chemotherapy with methylprednisolone (VAMP) with the addition of weekly cyclophosphamide (C-VAMP) as induction treatment followed by autografting in previously untreated myeloma. Br J Haematol 1997;97: 153-160.
14. Gore ME, Selby PJ, Millar B, Maitland J, McElwain TJ. The use of verapamil to overcome drug resistance in myeloma. Proc Am Soc Clin Oncol 1988;7:228.
15. Gore ME, Selby PJ, Viner C, Clark PI, Viner C, Clark PI, Meldrum M, Millar B, Bell J, Mainland JA, Milan S, Judson IR. Intensive treatment of multiple myeloma and criteria for complete remission. Lancet 1989;2:879-881.
16. Blade J, Samson D, Reece D, Apperley J, Bjorkstrand B, Gahrton G, Gertz M, Giralt S, Jagannath S, Vesole D. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high dose therapy and haemopoietic stem cell transplantation. Myeloma subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998;102:1115-1123.
17. Abeloff MD, Armitage JO, Lichter AS, Niederhuber JE. Clinical oncology. New York: 1995. p 1607.
18. Paccagnella A, Cartei G, Fosser V, Salvagno L, Bolzonella S, Chiarion Sileni V, Fiorentino MV. Treatment of multiple myeloma with M-2 protocol and without maintenance therapy. Eur J Cancer 1983;19:1345-1351.
19. Damiano JS, Cress AE, Hazlehurst LA, Shtil AA, Dalton WS. Cell adhesion mediated drug resistance (CAM-DR): Role of integrins and resistance to apoptosis in human myeloma cell lines. Blood 2000;93:1658-1667.